Glenmark Pharmaceuticals has agreed to pay out a further $25m in the US, “to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug,” the US Department of Justice has announced.
The case is linked to historical allegations that the firm between 2013 and 2015 “paid and received compensation prohibited by the anti-kickback statute through arrangements on price, supply and allocation of customers with other pharmaceutical manufacturers for a generic drug manufactured
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?